# Candel Therapeutics (CADL) — Earnings

CADL · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/cadl/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | −$0.09 |
| EPS estimate | −$0.16 |
| EPS surprise | +45.02% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Aug 14, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1841387/000095017025108450/cadl-20250630.htm) |

Candel Therapeutics last reported fiscal Q2 2025 results on August 14, 2025. The company posted a loss of $0.09 per share, narrower than the estimated loss of $0.16, a 45.02% beat. The table shows no revenue and no revenue estimate for the quarter. A year earlier, in Q2 2024, the loss was $0.74 per share.

Losses run through almost the whole table. Of the 17 quarters shown, 15 were losses. The two profits were Q4 2021 at $0.05 and Q1 2025 at $0.13 per share, and the widest loss was $1.46 in Q2 2021. Full-year losses grew from $0.65 per share in 2022 to $1.30 in 2023 and $1.75 in 2024. Revenue appears only in a few 2021 and 2022 quarters, at about $31,000 to $32,000. Against estimates the record is mixed, with 8 beats and 6 misses. No estimate was given for the first three quarters of 2024.

The table ends with Q2 2025 and holds no later quarter. In earlier years, Candel reported third-quarter results between November 9 and November 14 and fourth-quarter results in March. Newer quarters, once they appear here, will show whether results stay closer to break-even, as in the first half of 2025.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 14, 2025 | −$0.16 | −$0.09 | 45.02% | — | — |
| Q1 2025 | May 13, 2025 | −$0.37 | $0.13 | 134.70% | — | — |
| Q4 2024 | Mar 13, 2025 | −$0.23 | −$0.40 | -75.75% | — | — |
| Q3 2024 | Nov 14, 2024 | $0.00 | −$0.33 | 0.00% | — | — |
| Q2 2024 | Aug 13, 2024 | $0.00 | −$0.74 | 0.00% | — | — |
| Q1 2024 | May 14, 2024 | $0.00 | −$0.28 | 0.00% | — | — |
| Q4 2023 | Mar 28, 2024 | −$0.16 | −$0.38 | -137.50% | — | — |
| Q3 2023 | Nov 9, 2023 | −$0.19 | −$0.29 | -52.63% | — | — |
| Q2 2023 | Aug 10, 2023 | −$0.30 | −$0.33 | -10.52% | — | — |
| Q1 2023 | May 11, 2023 | −$0.35 | −$0.30 | 14.33% | — | — |
| Q4 2022 | Mar 30, 2023 | −$0.31 | −$0.18 | 41.20% | $13,000.00 | — |
| Q3 2022 | Nov 10, 2022 | −$0.35 | −$0.30 | 15.13% | $15,500.00 | $31,000.00 |
| Q2 2022 | Aug 5, 2022 | −$0.39 | −$0.14 | 64.27% | — | $31,000.00 |
| Q1 2022 | May 12, 2022 | −$0.09 | −$0.03 | 66.25% | $20,667.00 | — |
| Q4 2021 | Mar 29, 2022 | −$0.31 | $0.05 | 116.22% | $15,000.00 | $32,000.00 |
| Q3 2021 | Nov 12, 2021 | −$0.26 | −$0.69 | -163.96% | $13,333.00 | $31,000.00 |
| Q2 2021 | Sep 8, 2021 | −$0.23 | −$1.46 | -535.61% | $6,667.00 | — |

## Frequently Asked Questions

### When did Candel Therapeutics (CADL) last report earnings?

Candel Therapeutics last reported on Aug 14, 2025, covering fiscal Q2 2025.

### Did CADL beat earnings estimates?

Yes. Candel Therapeutics reported EPS of −$0.09 for Q2 2025 against a −$0.16 estimate — a 45.02% beat.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).